Active	Status	Sponsor type	Region	Phase	Filter
3 Active 1 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
TRS003 (bevacizumab biosimilar) / Zhejiang Teruisi Biopharma
ChiCTR1900024463: Phase III study for TRS003 in patients with advanced non-small cell lung cancer	Not yet recruiting	3	532		TRS003 + Paclitaxel + Carboplatin ;Bevacizumab + Paclitaxel + Carboplatin	Cancer Hospital Chinese Academy of Medical Sciences; Cancer Hospital Chinese Academy of Medical Sciences, Self-funding	Advanced Non-small Cell Lung Cancer
NCT04416035: A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC	Recruiting	3	608	RoW	TRS003, China-approved Bevacizumab, Carboplatin, Paclitaxel	Zhejiang Teruisi Pharmaceutical Inc.	Advanced Non-squamous Non-small-cell Lung Cancer	10/21	11/21
NCT05378867: A Study Assessing the Interchangeability Between TRS003 and Bevacizumab® For CRC	Not yet recruiting	3	126	NA	TRS003, China-approved Bevacizumab, mFOLFOX6	Zhejiang Teruisi Pharmaceutical Inc.	Metastatic Colorectal Cancer (CRC)	10/23	07/24